Evidence map›Paper›PMID 34337054›Full record

ArticleBioMed research international2021

SEMA4D Knockdown Attenuates

Mahsa Rezaeepoor, Golnaz Rashidi, Mona Pourjafar, Chiman Mohammadi, Ghasem Solgi, Rezvan Najafi

Open access · hybridAbstract read
In one paragraph

Article in BioMed research international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mahsa RezaeepoorDepartment of Immunology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-1158-3881
Golnaz RashidiDepartment of Immunology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-6734-9480
Mona PourjafarResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0002-7124-4577
Chiman MohammadiResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-4280-9409
Ghasem SolgiDepartment of Immunology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0001-8929-5658
Rezvan NajafiResearch Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.ORCID https://orcid.org/0000-0003-1326-1288
Hamedan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Semaphorin 4D (SEMA4D), a protein originally demonstrated to regulate the immune system and axonal growth cone collapse in the developing central nervous system, is overexpressed in various human malignancies, including colorectal cancer (CRC). This investigation was undertaken to examine the effects of SEMA4D silencing on the biological properties of the CRC cell line. SW48 cells were transfected with a siRNA-targeting SEMA4D. The mRNA expression of underlying pro- and antiapoptotic proteins including Bax, Bcl-2, P53, and caspase-3, cancer stem cell (CSC) markers, epithelial-mesenchymal transition (EMT) markers, MMP-2, and MMP-9 was examined using qRT-PCR. Further, the protein expression of E-cadherin and

Indexed as

Disease ProgressionGene Knockdown TechniquesAntigens, CDApoptosisbeta CateninCell Line, TumorCell MovementCell SurvivalColorectal NeoplasmsDown-RegulationEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansNeoplastic Stem CellsRNA, Small InterferingSemaphorinsAntigens, CDbeta CateninCD100 antigenRNA, Small InterferingSemaphorins

Identifiers

PMID34337054
PMCPMC8321723
OpenAlexW3186476877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.